Digital Healthcare, Medical Devices
Mindray North America | January 12, 2024
Mindray, a global developer of technologies and solutions for patient monitoring, anesthesia, and ultrasound, announced a five-year agreement with WakeMed Health & Hospitals (WakeMed), a leading health system in Raleigh, N.C. The nationally recognized 970-bed not-for-profit health care system selected Mindray's intuitive patient monitoring systems—including the BeneVision Distributed Monitoring System (DMS) and BeneVision N-series Patient Monitoring Systems—for its three hospitals.
As part of the agreement, approximately 2,300 monitoring devices will be installed in WakeMed's emergency and inpatient areas, across all acuity levels, to help assess and facilitate patient care, monitor vitals and condition changes in real-time, and provide seamless data integration during patient transport throughout its facilities.
"We are very excited to collaborate with WakeMed," stated Wayne Quinn, President, Mindray North America. Wayne continued, "Our purpose is to provide our customers with progressive technology that helps them deliver the highest quality care now and in the future, aligning with a shared vision of better healthcare for all. The contract with WakeMed underscores our commitment to ensuring the health system has access to tools and technologies that enable clinicians to work more efficiently while helping WakeMed fulfill its mission to improve the health and well-being of their community by providing outstanding and compassionate care to all."
"Mindray's monitoring technology will allow us to further improve patient safety, efficiency and clinical workflow as we continue to deliver life-changing care," said Neal Chawla, MD, Chief Medical Information Officer (CMIO) for WakeMed. "Alongside comprehensive patient monitoring, these innovative tools help prevent alarm fatigue and create a quieter, more restful environment for patients—a critical element to promote healing."
The BeneVision N-Series consists of six monitors with the same user interface. It allows healthcare facilities to choose their ideal display size and parameter capabilities, putting precise, relevant data at clinicians' fingertips. As the first-ever patient monitoring platform to incorporate capacitive touch screen technology across all of its monitors, N-Series enables clinicians to cut minutes off of clinical review, analysis and charting time, leading to increased efficiencies and driving positive patient outcomes. The N-Series' modular design expands, providing a scalable solution and the ability to flex from low acuity to high acuity, seamless data integration during transport, and flexible licensing options.
Mindray's BeneVision DMS provides continuous, real-time access and surveillance across large and small healthcare networks and integrates and displays patient information from networked bedside monitors, vital signs monitors, wireless transport solutions, and telemetry transmitters – supporting up to 1,200 devices across the enterprise, locally, and remotely. The BeneVision DMS enables clinicians to observe, manage and document a patient's condition in support of high-quality, patient-centric care, from admission to discharge.
Mindray is a leading developer, manufacturer, and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of lifesaving tools across three primary business segments: medical imaging, patient monitoring and life support, and in-vitro diagnostics. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in Silicon Valley, with additional facilities in major international markets around the world.
About WakeMed Health & Hospitals
Serving the community since 1961, WakeMed is a not-for-profit health care system founded and based in Raleigh, N.C. WakeMed exists to improve the health and well-being of our community by providing outstanding and compassionate care to all. WakeMed's 970-bed system comprises a network of facilities throughout the Triangle area, including three full-service hospitals, seven emergency departments, a dedicated Children's Hospital and Rehabilitation Hospital, more than 90 physician offices and Wake County's only Level I Trauma Center. WakeMed's mission-driven team includes more than 10,300 employees, 1,400 volunteers and 1,300 affiliated physicians, along with the more than 700 physicians and providers with WakeMed Physician Practices – all representing the best minds and the biggest hearts and the finest quality in health care and community health.
Axxess | January 23, 2024
Axxess, the leading global technology innovator for healthcare at home, launched a new product called Axxess Connect, a groundbreaking interoperability solution. This new product will revolutionize the way Axxess users connect and share data with healthcare providers and specialists, further enhancing care coordination, improving patient outcomes and driving the future by enabling new care models and value-based care.
"Axxess Connect is a new benchmark for interoperability in healthcare," says Tim Ingram, Executive Vice President of Interoperability at Axxess. "By working with our partner Kno2 we can now connect our solutions to help accelerate the exchange of health information securely across any network. This means our clients will have easier access to a broader range of providers and specialists, making data sharing and referrals more efficient."
By being Kno2 Connected™, Axxess Connect, enables the secure, effortless, and maximized exchange of patient information across patients, providers, payers and HIT vendors. The solution meets data security and compliance requirements in accordance with HITRUST and HIPAA regulation for privacy, data sharing and healthcare communication standards supported by national and regional frameworks including Direct Trust, Carequality and most recently, TEFCA. This ensures that patient data is interoperable, secured and protected when shared across systems.
"Our collaboration with Kno2 not only improves the overall experience for our users, but it also reduces the administrative load on healthcare providers," said Ingram. "By minimizing time spent on administrative tasks, our clients can focus more on providing quality patient care."
Added Theresa Bell, Co-founder, President and Chief Technology Officer of Kno2: "By seamlessly connecting Axxess users with healthcare providers and specialists, we are breaking down barriers and revolutionizing the way data is shared in every care setting. Axxess Connect represents the power of the partnership and the value of being Kno2 Connected. Together, we are revolutionizing care delivery and thoughtfully solving healthcare's biggest problems."
Axxess Connect will first be available to Axxess Palliative Care clients before eventually being rolled out to the entire Axxess suite of solutions for home health, hospice and home care.
Axxess is the leading global technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 5 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. Multiple independent certifications have confirmed that Axxess has the most secure and industry-compliant software available for providers. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."
PureHealth | January 16, 2024
PureHealth, the largest healthcare platform in the Middle East, has announced the successful completion of its strategic acquisition of Circle Health Group, UK’s largest independent operators of hospitals, marking a significant milestone in the company's global expansion strategy. The completion of this deal, which has achieved regulatory approvals in record time, signifies PureHealth’s exceptional operational capabilities and commitment to international growth.
The completion of this transaction further strengthens PureHealth’s commitment to becoming a leading global player in healthcare. With a vision aligned with the UAE leadership to promote wellbeing and enhance healthcare services, PureHealth is dedicated to continuously improving patient experience and adopting the most advanced clinical practices. The company’s expansion into the UK healthcare market reflects its focus on advancing the science of longevity and unlocking time for humanity.
Hamad Al Hammadi, Chairman of the Board of Directors of PureHealth, said: “We are pleased to complete the acquisition of Circle in record time. This remarkable achievement epitomises PureHealth's operational excellence and strategic adaptability in broadening its international impact. After investing in Ardent Health USA, this is PureHealth’s second international acquisition, and we look forward to building our portfolio internationally.”
Farhan Malik, Founder and Managing Director of PureHealth, commented: “Completing the acquisition of Circle is a strategic leap forward for PureHealth. This acquisition is more than an expansion; it's a significant stride towards establishing PureHealth as a global healthcare platform. We are not just investing in the future of healthcare; we are shaping it to be more connected, innovative, and accessible on a global scale. This move aligns with our vision of pioneering a healthier future for all and underscores our commitment to elevating the global position of Abu Dhabi in the healthcare sector and revolutionising healthcare services globally. We look forward to fostering long term partnerships within the UK’s healthcare ecosystem.”
Valued at c.USD 1.2 billion before debt, this acquisition marks a significant investment in the future of healthcare, positioning PureHealth at the forefront of international healthcare innovation and service provision.
Building upon this significant momentum, PureHealth is advancing its expansion strategy in 2024. This strategic vision includes not only acquisitions in locally, but also international markets building a global healthcare platform.
As PureHealth moves forward with its strategic global expansion, it remains committed to its mission of delivering unrivalled healthcare experiences through innovation, technology-driven solutions, and collaboration. This transaction not only enhances PureHealth's services and presence in the international healthcare landscape but also solidifies the company’s position as a leader in the healthcare industry, dedicated to improving lives and fostering healthier communities worldwide, and taking PureHealth from Abu Dhabi to the World.
By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth is the largest healthcare platform in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more. With groundbreaking innovations at the forefront of healthcare, the company is on a mission to unlock time for humankind.
Medtronic | January 05, 2024
Medtronic plc a global leader in healthcare technology, announced it has received CE Mark for its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniature, leadless pacemakers.
Micra AV2 and Micra VR2, the world's smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.2
With approximately 40% more battery life compared to previous generations,1 Medtronic projects the battery life of Micra AV2 and Micra VR2 is nearly 16 and 17 years, respectively.3 This means more than 80% of patients who receive a Micra may only require one device for life.3
This CE Mark milestone follows U.S. Food and Drug Administration approval for the Micra AV2 and VR2 devices in 2023.
In addition to size and longevity benefits, Micra devices are also the only leadless pacemakers with remote monitoring capabilities, which allow a doctor or clinic to check on a patient's heart device without the need for a patient to travel to their clinic for an in-person appointment. Other patient benefits of remote monitoring may include a reduction in hospitalizations and increase in sense of security.4,5
"For more than eight years, our Micra leadless pacemakers have provided meaningful benefits to people in Europe who require a pacemaker. Now, these patients have access to the latest leadless pacing technology that, for most of them, may be the only device they will ever need," said Robert C. Kowal, M.D., Ph.D., general manager, Cardiac Pacing Therapies within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic.
"The first generation of leadless Micra pacemakers demonstrated a significant reduction in major complications, and this next generation of Micra brings several additional benefits including greater longevity, and specifically for the Micra AV2, new algorithms to optimize AV synchrony at faster heart rates while requiring less in-office programming," said Prof. Dr. Christophe Garweg, Cardiologist at University Hospitals of Leuven, Belgium. "These advantages likely will expand the use of the leadless pacemaker to more patients."
Globally, more than 200,000 patients have received Micra pacemakers.6 Comparable in size to a large vitamin, Micra pacemakers are less than one-tenth the size of traditional pacemakers. Unlike traditional pacemakers, Micra pacemakers do not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are eliminated, and there is no visible sign of the device.
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.